Sort
10,766 grants matching “checkpoint inhibitor”
Integration of stromal targeting agents with immune checkpoint therapy
$344,496Lei Zheng · Johns Hopkins University · P01 · FY2025 · CA
Integration of stromal targeting agents with immune checkpoint therapy
$344,496Lei Zheng · Johns Hopkins University · P01 · FY2021 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$344,450Raoul Tibes · Mayo Clinic Arizona · R01 · FY2015 · CA
Targeting Stat3 to Improve Immunotherapy
$344,450Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2010 · CA
PQD2 Rational Combination of Standard Agents and Immunotherapy to Treat Myeloma
$344,450Marta Chesi · Mayo Clinic Arizona · R01 · FY2017 · CA
Targeting Stat3 to Improve Immunotherapy
$344,450Hua E Yu · Beckman Research Institute/City Of Hope · R01 · FY2009 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$344,450Raoul Tibes · Mayo Clinic Arizona · R01 · FY2013 · CA
CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML
$344,450Raoul Tibes · Mayo Clinic Arizona · R01 · FY2016 · CA
Developing Novel Therapeutic Approaches Targeting Macrophages in GBM
$344,441Y. Alan Wang · Indiana University Indianapolis · R01 · FY2024 · CA
Interplay between Cdh1 and major regulatory pathways in human cancer
$344,273Wenyi Wei · Beth Israel Deaconess Medical Center · R01 · FY2010 · GM
Microenvironment and Arsenic Lung Tumorigenesis
$344,250Gang Chen · University Of Kentucky · R01 · FY2022 · ES
Intestinal Cell Growth Control: Role of Tyrosine Kinases
$344,223Christine Ann Cartwright · Stanford University · R01 · FY2015 · DK
A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy
$344,080Jianqin Lu · University Of Arizona · R01 · FY2025 · CA
Intestinal Cell Growth Control: Role of Tyrosine Kinases
$344,032Christine Ann Cartwright · Stanford University · R01 · FY2014 · DK
Immunosuppression and Metabolic Rewiring in Tumor-infiltrating Neutrophils
$343,968Xin Lu · University Of Notre Dame · R01 · FY2024 · CA
Development of a targeted delivery platform for checkpoint inhibitors
$343,925Kun Cheng · University Of Missouri Kansas City · R01 · FY2019 · CA
Intestinal Cell Growth Control: Role of Tyrosine Kinases
$343,760Christine Ann Cartwright · Stanford University · R01 · FY2012 · DK
PROGRESSION OF T CELL LYMPHOMA LINES TO IL2 INDEPENDENCE
$343,720Thomas Jefferson University · R01 · FY2000 · CA
Modulators of p53 Expression and Function
$343,545Andrei V Gudkov · Roswell Park Cancer Institute Corp · R01 · FY2007 · CA
Dual-pronged nano-drug delivery using plant virus-like particles
$343,474Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2025 · CA
The role of HIF2alpha in colon carcinogenesis
$343,473Yatrik M Shah · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$343,436David E Fisher · Massachusetts General Hospital · P01 · FY2020 · CA
Targeting Endoplasmic Reticulum Stress Sensor IRE1 to Enhance Chemotherapy Sensitivity in MYC-driven breast cancer
$343,397Xi Chen · Baylor College Of Medicine · P50 · FY2020 · CA
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC
$343,389Xingming Deng · Emory University · P50 · FY2019 · CA
Targeting immune stroma interactions in pancreatic cancer
$343,355Gregory B. Lesinski · Emory University · R01 · FY2019 · CA